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Abstract
The detection of low virus concentrations in biological matrices, especially stool samples, is facing significant limitations as far as common
diagnostic methods (enzyme-linked-immunosorbent assay (ELISA) or quantitative real-time PCR (qPCR)) are considered. Here the
development of a new immuno real-time PCR (iPCR) is described and its performance in the detection of human adenoviruses (HAdVs)
in spiked stools is compared with those of ELISA and qPCR assays. For the iPCR, detection of the sandwich formed by the complexation
of capture antibody-antigen-detection antibody was performed by qPCR thanks to the substitution of peroxydase by a chimeric DNA.
This modification increased the detection sensitivity 200-fold compared to ELISA. The direct qPCR results revealed that only 0.3–9.5% of
the spiked HAdV were detectable, resulting from important losses of DNA occurring at the extraction step. This step was not necessary
in the iPCR workflow, avoiding this drawback. The losses of viral particles occurred at the elution step from the stool only. The
recovery rate of the iPCR was thus better and ranged between 21 and 54%. As a result, iPCR enabled the detection of lower virus
concentrations in stool samples compared to those detected by ELISA and qPCR. The iPCR could be considered as a ‘hyper sensitive
ELISA’ for early detection of HAdV infections, especially in the case of immunocompromised patients after haematopoietic stem cell
transplant.
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Introduction
Human adenoviruses (HAdVs) are non-enveloped, icosahedral,
double-stranded DNA viruses ranging in size between 80 and
110 nm in diameter. Currently, all described human types are
dispatched into 54 types representing seven species (A-G),
which belong to the genus Mastadenovirus in the Adenoviridae
family [1]. They are commonly responsible for a wide range of
respiratory, gastrointestinal or ophthalmic illnesses. All HAdV
types are excreted in very high numbers in faeces of infected
people, regardless of the initial infection site [2]. Some HAdVs
can establish long-lasting but indiscernible infections. As a
result, the infected person sheds viruses unknowingly, and can
then serve as a source of infection for other individuals [3].
After recovery from illness, HAdVs, especially the members of
the HAdV-C species, may maintain latent persistent infections
in the tonsils, the adenoids and other lymphoid tissues [4].
Some types (e.g., 1, 2, 3 and 5) are continuously present in the
population. Most people have thus been exposed (primary
infection) and at least 90% of the human population are
positive to one or more HAdV antibodies [5,6], even though
no acute disease has been declared. On the contrary, HAdV
infections (primary infections or reactivation of latent viruses)
in immunocompromised people tend to become invasive, and
the fatality rate may be as high as 50% [7]. After haematopoi-
etic stem cell transplantation, the immune system is weakened
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and many viruses are identified as a major risk for patients
[8,9]. HAdVs have therefore emerged as life-threatening
agents in severely immunocompromised patients, such as
haematopoietic stem cell recipients [10].
The main methods used to detect HAdVs in clinical samples
(blood and stool) are antigen detection assays, such as
enzyme-linked-immunosorbent assay (ELISA), immunofluores-
cence or immunochromatography tests, or molecular biology
assays such as quantitative real-time PCR (qPCR).
Immuno-detection methods are of particular interest because
they yield results quickly, despite their low sensitivity. They are
generally used for screening HAdVs in stool samples or
respiratory fluids from infected children, because these kinds
of samples are heavily loaded with HAdV particles in the case of
infection. The qPCR is considered to be a very sensitive, robust
and fast technique. Recent European guidelines for diagnostis
and treatment of adenovirus infection in stem cell transplanta-
tion (ECIL-4) recommend qPCR for monitoring HAdVs of
high-risk patients [11], as previously suggested [12]. Using such a
tool, an interest in screening HAdVs in stool samples instead of
blood has been highlighted, because the HAdV viral load in stool
samples precedes the presence of HAdVs in blood [13,14].
The qPCR workflow requires a preliminary viral DNA
isolation. This extraction and purification of nucleic acids is a
critical step in the molecular detection of viruses from
complex samples such as stools [15], even though most of
the extraction kits are well adapted for use in a clinical setting.
At this stage, DNA losses can occur, resulting in an
under-estimation of HAdV concentration. Moreover, the
presence of potential PCR inhibitors found in stool specimens
(as lipids, polysaccharides and bile salts) can also perturb the
qPCR reaction and lead to false-negative results [16].
An alternative method, named immuno-PCR has been
developed during the last decades [17] and is considered to be
a promising ultrasensitive diagnostic tool despite its still scarce
routine application [18]. This technique combines the speci-
ficity of the antibodies with the amplification power and the
sensitivity of (q)PCR, without a nucleic acid extraction step. In
this context, the aim of this study was (i) to develop and
optimize an immuno real-time PCR (iPCR) to detect HAdV
particles in stool samples and (ii) to compare the performance
of this newly developed assay with the existing routinely used
methods, sandwich ELISA and qPCR.
Methods
Adenoviruses
Multiplication of HAdV-2 (Health Protection Agency culture
collection NCPV#213) and HAdV-41 (American Type Culture
Collection VR-930) was performed by infection of human
embryonic kidney cells 293A (R705-07; Life Technologies,
Halle, Belgium) as previously described [19]. The concentra-
tions of viral stocks were estimated by a most probable
number assay, and the concentration expressed in most
probable number of cytopathogenic units per millilitre
(MPNCU/mL).
Stool samples and spiking experiments
Stool samples from a 3-year-old child not infected by HAdVs
(detection performed with ELISA, qPCR and iPCR) were used
for spiking experiments. Stool samples were spiked within a
range of 101–108 MPNCU/450 mg of stool of HAdV-2 and
HAdV-41 using a syringe and mixed with a Potter-Elvehjem
homogenizer. Elution of viruses was performed by adding
2 mL phosphate-buffered saline (PBS: 137 mM NaCl, 2.7 mM
KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4,2H2O; pH = 7.4) and
four 2-mm-diameter glass beads. Stools were dissolved in PBS
by vortexing for 1 h at 500 rpm at room temperature (RT).
Samples were then centrifuged at 3000 g for 60 min at 4°C.
The collected supernatant was used to perform analysis using
the three different detection methods.
Antibodies
The antibody isotypes 8C4 and 1E11 (Hytest, 3AV13) were
used as capture and detection antibodies, respectively. The
detection antibody 1E11 was biotinylated. Both antibodies
were directed against genus-specific hexon antigen. The
targeted Mastadenovirus genus includes all the human adeno-
virus types, among others. The specificity of both antibodies
was validated through the sandwich ELISA procedure using the
human types HAdV-1, -2, -3 -6, -19 and -41, belonging to four
distinct human adenovirus species (data not shown).
Sandwich ELISA
Step 1. Fifty microlitres of 8C4 capture antibody at a final
concentration of 44 mg/mL in coating buffer (4.3 mg/L NaH-
CO3; 5.3 mg/L Na2CO3; pH 9.4) were placed in wells of a
polypropylene 96-well PCR plate (4346907; Life Technologies)
and incubated at 37°C for 1 h. Non-binding antibodies were
removed by five washings with 200 lL of PBS-T (PBS, 0.1%
Tween-20).
Step 2. One hundred and fifty microlitres of casein 1%
(solution in PBS) were placed in wells and incubated at 37°C
for 15 min, followed by five washings with PBS-T.
Step 3. Fifty microlitres of sample (or dilutions) were placed
in wells (dilutions were performed in casein 1%) and incubated
at RT for 1 h, followed by five washings with PBS-T.
Step 4. Fifty microlitres of biotinylated 1E11 detection
antibody (final concentration, 11 mg/mL in casein 1%) were
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placed in wells and incubated for 1 h at RT. Non-binding
antibodies were eliminated by three washings with PBS-T.
Three additional washings were performed with PBS contain-
ing 1% of casein.
Step 5. Fifty microlitres of streptavidin-conjugated horse-
radish peroxidase (HRP) (PO397; Dakodiagnostics) at a final
concentration of 1/7500 (diluted in casein 1%) were added to
wells and incubated for 30 min in the dark at RT, followed by
five washings with PBS-T.
Step 6. Quantification of antigens was indirectly measured
by activity of HRP. Fifty microlitres of 3,30,5,50-tetramethyl-
benzidine (1-StepTM Ultra TMB-Elisa, Fisher Scientific, Tournai,
Belgium) were placed in wells and incubated in dark for 15 min
at RT. The reaction was stopped by the addition of 50 lL 1 M
H2SO4, and the absorbance was read at 450 nm with a Synergy
2 multi-mode microplate reader (Biotek, Bad Friedrichshall,
Germany).
Immuno real-time PCR
Steps 1, 2, 3 and 4 were the same as previously described for
sandwich ELISA. For steps 5 and 6, the peroxidase was
substituted by a 50-end biotinylated DNA reporter to form a
streptavidin-DNA reporter complex, which was then quanti-
fied by qPCR (Fig. 1). The DNA reporter design and its
detection system were previously described [20]. This DNA
molecule is a combination of two DNA fragments from
eukaryotic and prokaryotic plasmids.
Step 5. Fifty microlitres of streptavidin-DNA reporter
complex (diluted in casein 1%) were placed in wells and
incubated for 15 min at RT, followed by five washings with WB
and ten washings with DNase/RNase free water.
Step 6. DNA reporter quantification was performed using
Mesa Green qPCR MasterMix Plus Low Rox (Eurogentec,
Liege, Belgium) with the following final concentrations in 50 lL
final volume: 1X MasterMix, 0.3 lM forward and reverse
primers, on a 7500 Fast Real-Time PCR System (Life
Technologies). Thermal cycling conditions were: initial 5 min
at 95°C for activation of MeteorTaq polymerase, followed by
45 cycles of 15 s at 95°C and 1 min at 60°C, and a final
dissociation step. Primer specificity was controlled by the
presence of a single peak in the melting curves.
Direct qPCR
DNA was extracted from 140 lL of viral stocks using the
QIAamp viral RNA mini kit (Qiagen, Venlo, the Netherlands).
From the supernatant of stool samples, viral DNA was
extracted by the QIAamp viral RNA mini kit and QIAamp
DNA stool mini kit (Qiagen). The quantification of the
adenovirus DNA was performed by a previously developed
qPCR system using degenerated primers and a TaqMan probe
[21]. The upstream and downstream primer sequences were
50-CWT ACA TGC ACA TCK CSG G-30 and 50-CRC GGG
CRA AYT GCA CCA G-30, respectively. The sequence (50–30)
of the Ad(ACDEF) probe was 6FAM-CCG GGC TCA GGT
ACT CCG AGG CGT CCT-BHQ1. The detection of qPCR
inhibitors in DNA extract from stools was performed by
adding the equivalent of 105 copies/reaction of HAdV-2 DNA
in extracted DNA from a non-spiked stool sample. The
detected concentrations in a stool sample (Cstool) were
compared with concentrations obtained for the same HAdV-2
DNA concentration in water (Cpur DNA). The potential
inhibition was expressed as a percentage and calculated as
follows: 100  [(Cstool 9 100)/Cpur DNA].
Definitions of detection and quantification limits
For qPCR, the limit of detection (LOD) was measured as the
concentration of DNA that gives a signal significantly different
from the negative control.
For sandwich ELISA, the LOD was defined as the value of
the negative control + two standard deviations. The limit of
FIG. 1. Schematical representation of the iPCR procedure and duration of each step. The general setup of iPCR is similar to that of antigen
detection through ELISA. The DNA reporter is amplified by real-time PCR for signal generation. The duration of the whole iPCR workflow is about
6 h, including the required time for all the washing steps.
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quantification (LOQ) was defined as the minimum value of the
linear dynamic range observed on the standard curve.
For iPCR, the LOD was defined as the lower concentration
giving a difference of 2.2 Ct (corresponding to 2 SD) compared
with that given for the negative control [20]. The LOQ was
defined as the lowest level of DNA detected that provided an
acceptable level of precision (i.e. 3/3 replicates amplified with a
Ct standard deviation inferior to 0.8 from the mean Ct).
Results
Sensitivities and performances of sandwich ELISA, real-time
PCR and iPCR
In order to define the LOD, LOQ and the dynamic range of
the different techniques, a range of concentrations between 10
and 108 viruses/reaction of both HAdV types (HAdV-41 and
HAdV-2) in suspension in sterile milliQ water were analysed
by ELISA, qPCR and iPCR. The results are shown in the
Table 1. Standard curves obtained for both HAdV-2 and
HAdV-41 using the iPCR assay are presented in Fig. 2.
Detection of HAdV in spiked stool samples
For the qPCR analysis, the recovery rate ranged from 0.3 to
9.5% (Fig. 3) and seemed to be proportional to the viral
concentration (i.e. recovery rate decreased as the added
concentration decreased). Due to this low recovery rate, it
was estimated that the lowest detectable virus concentration
in a stool sample was about 106 particles per gram of stool
(Table 1). Similar results were obtained using the QIAamp
DNA stool kit (Qiagen) for the DNA extraction (yields of
detection ranging from 0.2 to 5%).
Using sandwich ELISA, the losses of viral signals were less
important than the ones occurring during the qPCR assay.
Considering that all values below this threshold were negative,
the lower detected concentration of HAdV-2 was 2.5 9 105
MPNCU/reaction, corresponding to an added concentration
of 5.0 9 105 MPNCU/reaction. For HAdV-41, the lower
positive concentration was 1.2 9 105 MPNCU/reaction, cor-
responding to an added concentration of 2.1 9 105 MPNCU/
reaction (Fig. 3). Thus the recovery rate ranged from 13 to
54% (Fig. 3), but the LOQ (7.3 9 104 MPNCU/reaction) is
considered here to be the restrictive factor. As a consequence,
the lowest detectable virus concentration was superior to 107
particles per gram of stool (Table 1).
Using iPCR, recovery rate ranged from 21 to 59% (Figs 2
and 3). A better detection of HAdV-2 was observed, with a
yield ranging from 41 to 59%. Recovery rates for HAdV-41
ranged from 21 to 36%. Additionally, the better detection limit
of iPCR allowed the quantification of lower concentrations of
HAdVs in stool samples, as detected by direct qPCR. Thus
using iPCR, positive results were obtained for virus concen-
trations superior or equal to 5.104 particles per gram of stool
sample (Table 1).
Discussion
Today qPCR-based assays have been established as a standard
diagnostic tool for detection of HAdVs in any clinical material
from immunocompromised patients due to their technical
benefits (high sensitivity and specificity, and rapid and quan-
titative detection). In this study, a new diagnostic tool, based
on a combination of immuno-detection with a successive
qPCR, is proposed for the detection of HAdVs, especially in
stool samples where detection is known to be often tricky.
The usefulness of the iPCR assay has already been demon-
strated for several viral antigens (e.g. noroviruses and rotavi-
ruses), with detection of low concentrations in stool samples
[22,23].
TABLE 1. Characteristics of the three detection methods: ELISA, iPCR and qPCR
ELISA sandwich qPCR iPCR
HAdV-2 HAdV-41 HAdV-2 HAdV-41 HAdV-2 HAdV-41
Limit of detection
(MPNCU or genome
copies/reaction)
1.2 9 104 2 9 104 2 9 101 2 9 101 5 9 101 9 9 101
Limit of quantification
(MPNCU or genome
copies/reaction)
9.7 9 104 7.3 9 104 2 9 101 2 9 101 1.3 9 102 1.9 9 102
Dynamic range
(MPNCU or genome
copies/reaction)
9.7 9 104–2.5 9 107 7.3 9 104–9 9 106 2 9 101–4 9 107 2 9 101–1.5 9 107 1.3 9 102–1.6 9 104 1.9 9 102–5 9 104
Lowest detectable
concentration in
stools
(MPNCU or genome
copies/g of stool)
4.4 9 107 1.9 9 107 1.2 9 106 4.5 9 106 7 9 104 5.3 9 104
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For detection by immuno-detection tools, viral particles
must be released beforehand from stool samples by an
elution step (transfer of viruses in the aqueous phase by
mechanical dispersing of the stool in PBS), which can be a
major cause of virus loss. Also, in order to reduce the
concentration of interfering components within the eluate,
stool samples were clarified by centrifugation before the
analysis [22]. However, in complex matrices such as stools, a
large concentration of interfering components could persist
in the eluate, even with a preliminary clarification step,
leading to an impact on recovery rates as observed in the
present study.
The iPCR procedure developed here displays an LOD of 50
purified viral particles per reaction, indicating that its sensitivity
is about 200-fold higher than that of the sandwich ELISA assay
(104 purified viral particles). These findings are consistent with
previous reports on iPCR, which describe a sensitivity
improvement between 100- and 1000-fold compared to ELISA
[18,22]. In stool samples, iPCR and sandwich ELISA exhibit
similar recovery rates, which are considered as high. This can
be easily explained by the identical first step of antigen-anti-
body detection in both methodological approaches. The
unrecovered viruses are either sequestered in stools [22] or
not detected due to interference occurring at the
immuno-detection stage. Some compounds, such as lipids or
some proteins, are known to hinder the antigen-antibody
reaction by modifying and/or neutralizing fixation sites of
antigens and/or antibodies [24,25].
A drawback of iPCR is a high background noise, mainly due
to non-specific binding of chimeric DNA on the walls of wells
[26]. To avoid this phenomenon, chimeric DNA could be
coupled with a detection antibody before the addition to wells
[26,27]. The background noise may thus be reduced, resulting
in improved detection sensitivity.
According to our results, iPCR sensitivity is comparable to
that of qPCR using purified viral suspensions. However, iPCR
does not require a DNA extraction and purification step. This
is an asset in the analysis of complex clinical samples, such as
stools. Our results show that a maximum of 9.5% of spiked
HAdVs in stool samples were detectable using direct qPCR,
while the detection rate of iPCR can reach 59%. Important
DNA losses occurring during the nucleic acids extraction step
can certainly explain these findings. A study shows that only
0.1% of spiked HAdV-2 in stool samples is detected by qPCR,
regardless of the extraction kit used [15]. The results of the
latter study highlighted a considerable loss of DNA equal to or
higher than 3 log10 using three different extraction kits,
including the QIAamp viral RNA mini kit. The amplification
reaction can also be hindered by some interfering components.
Two studies on extraction and detection of coronaviruses in
stools demonstrated that PCR inhibitors present in nucleic
acid extracts could interfere with the performance of the
qPCR [28,29]. In the present work, low PCR inhibition was
observed (<5%), indicating that the poor HAdV detection using
qPCR was principally due to the low DNA extraction
efficiency.
In conclusion, the two major drawbacks of qPCR, loss of
viral DNA occurring at the extraction step and the PCR
inhibition, when used for the analysis of stool samples can
be avoided by using iPCR. Indeed, the numerous washing
steps occurring in the iPCR workflow allow eliminating a
large part of the qPCR inhibitors [18], and a viral DNA
FIG. 2. Standard curves obtained by the
optimized iPCR for HAdV-2 and HAdV-41
strains. The mean Ct for each dilution was
determined from 10 replicates.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O1010–O1016
O1014 Clinical Microbiology and Infection, Volume 20 Number 12, December 2014 CMI
purification step is not needed. The developed technique is
powerful and allows detection of small amounts of HAdV
particles in stool samples. To our knowledge this is the first
description of iPCR for HAdVs. It improves our ability to
decrease the detection limit of HAdVs in complex biological
matrices and thus avoid the underestimation of viral
concentrations. Its ability can be particularly interesting for
the early detection of HAdVs in immuno-compromised
patients. An early detection of HAdVs in stools should allow
the rapid implementation of treatments using antivirals or
adoptive immunotherapy to prevent the dissemination of the
infection.
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